Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
    • AGM Invitations
  • InderesTV
  • Forum
  • Discovery
  • Om os
    • Fulgte selskaber
    • Team

Photocure

Mindre end 1K følgere

PHO

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Investorkonsensus

Photocure is a medical technology company. The company specializes in photodynamic technology solutions. The solutions are used to treat diseases that cause bladder cancer and HPV. The main markets are dermatology and oncology, where the products are used by hospitals and research institutes worldwide. The company was founded in 1993 and is headquartered in Oslo, Norway.

Læs mere
Markedsværdi
-
Aktieomsætning
-
Omsætning
532,58 mio.
EBIT %
-0,14 %
P/E
-
Udbytteafkast, %
-
Finanskalender
4.5
2026

Generalforsamling '26

7.5
2026

Delårsrapport Q1'26

29.7
2026

Delårsrapport Q2'26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelsefor 14 timer siden

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Photocure
Pressemeddelelsefor 14 timer siden

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Photocure
Selskabsmeddelelse3.3.2026, 09.35

Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Photocure

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse3.3.2026, 09.34

Photocure: Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Photocure
Pressemeddelelse27.2.2026, 09.17

Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe

Photocure
Selskabsmeddelelse18.2.2026, 06.00

Photocure ASA: Results for the fourth quarter of 2025

Photocure
Selskabsmeddelelse18.2.2026, 06.00

Photocure ASA: Results for the fourth quarter of 2025

Photocure
Selskabsmeddelelse11.2.2026, 16.06

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

Photocure
Selskabsmeddelelse11.2.2026, 16.06

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

Photocure
Selskabsmeddelelse12.1.2026, 16.42

New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Photocure
Pressemeddelelse12.1.2026, 16.00

Photocure: New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Photocure
Selskabsmeddelelse29.12.2025, 13.22

PHO: Financial calendar

Photocure
Selskabsmeddelelse8.12.2025, 07.00

The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Photocure
Pressemeddelelse8.12.2025, 07.00

Photocure: The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Photocure
Selskabsmeddelelse19.11.2025, 07.00

PHO: New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management

Photocure
Pressemeddelelse19.11.2025, 07.00

Photocure: New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management

Photocure
Selskabsmeddelelse31.10.2025, 07.24

Photocure ASA: Notification of primary insider transaction

Photocure
Selskabsmeddelelse31.10.2025, 07.24

Photocure ASA: Notification of primary insider transaction

Photocure
Selskabsmeddelelse29.10.2025, 06.00

Photocure ASA: Results for the third quarter of 2025

Photocure
Selskabsmeddelelse29.10.2025, 06.00

Photocure ASA: Results for the third quarter of 2025

Photocure
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.